type of report	**Current report**
number	61/2014
company	Pharmena Spółka Akcyjna

Obtaining permission for a change in the report on clinical trials on innovative anti-atherosclerosis medicinal product 1-MNA

With reference to the Company's Strategy for 2012-2015 (published in current report no. 16/2012 of 13th April 2012) and the communication on the progress in clinical trials on innovative anti-atherosclerosis medicinal product 1-MNA (published in current report no. 56/2014 of 6th November 2014), the Management Board of PHARMENA S.A. informs that on 28th November, Health Canada (the institution supervising clinical trials in Canada) gave permission ("Notice of Authorization") to introduce a change in the report on phase II clinical trials ("Proof of Concept") on innovative anti-atherosclerosis medicinal product based on the active substance 1-MNA (the working name of the medicinal product is TRIA-662). Cortria Corporation put forward a motion to introduce a change in the report on trials as to the selection criteria regarding HDL-c cholesterol. This parameter will not be taken into account in the patient selection criteria, whereas any changes in its level will still be monitored during the trial. Health Canada gave permission to introduce the change in the report on clinical trials in the form proposed by Cortria Corporation.

The aim of the phase II clinical trial on the 1-MNA anti-atherosclerosis medicinal product is to establish the effective dose of the medicinal product and confirm the lack of side effects in humans in the tested doses. The supervisory institution for the trial is the Montreal Heart Institute.

The Montreal Heart Institute is a leading research centre in Canada, specialising in cardiology, and one of the largest institutes of this type in the world. It is a world-renowned institute that has introduced many innovatory solutions nationally and worldwide. For more information see www.icm-mhi.org.

Phase II clinical trials ("Proof of Concept") are financed from funds raised in the issue of series D shares.

This information is made public due to the fact that conducting phase II clinical trials is necessary for commercialisation of the 1-MNA anti-atherosclerotic medicinal product project, while potential revenues from the medicinal product commercialisation may have a very significant impact on financial results and market valuation of the Issuer.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska - Vice President of the Board